S3-Guideline “Exocrine Pancreatic Carcinoma” 20071 ... - DGVS

478
Leitlinie
80 Kim JE, Lee KT, Lee JK et al. Clinical usefulness of carbohydrate antigen
19–9 as a screening test for pancreatic cancer in an asymptomatic
population. J Gastroenterol Hepatol 2004; 19: 182–186
81 McWilliams RR, Rabe KG, Olswold C et al. Risk of malignancy in firstdegree
relatives of patients with pancreatic carcinoma. Cancer 2005;
104: 388–394
82 Klein AP, Brune KA, Petersen GM et al. Prospective risk of pancreatic
cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64:
2634–2638
83 Bartsch DK, Sina-Frey M, Lang S et al. CDKN2A germline mutations in
familial pancreatic cancer. Ann Surg 2002; 236: 730–737
84 McFaul CD, Greenhalf W, Earl J et al. Anticipation in familial pancreatic
cancer. Gut 2006; 55: 252–258
85 Tersmette AC, Petersen GM, Offerhaus GJ et al. Increased risk of incident
pancreatic cancer among first-degree relatives of patients
with familial pancreatic cancer. Clin Cancer Res 2001; 7: 738–744
86 Brentnall TA. Management strategies for patients with hereditary
pancreatic cancer. Curr Treat Options Oncol 2005; 6: 437–445
87 Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia
in high-risk individuals: an EUS-based approach. Clin Gastroenterol
Hepatol 2004; 2: 606–621
88 Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic
neoplasia in high-risk individuals: a prospective controlled study.
Clin Gastroenterol Hepatol 2006; 4: 766–781; quiz 665
89 Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer
in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:
1447–1453
90 Lim W, Olschwang S, Keller JJ et al. Relative frequency and morphology
of cancers in STK11 mutation carriers. Gastroenterology 2004;
126: 1788–1794
91 Lynch HT, Brand RE, Hogg D et al. Phenotypic variation in eight extended
CDKN2A germline mutation familial atypical multiple mole
melanoma-pancreatic carcinoma-prone families: the familial atypical
mole melanoma-pancreatic carcinoma syndrome. Cancer 2002;
94: 84–96
92 Rulyak SJ, Brentnall TA, Lynch HT et al. Characterization of the neoplastic
phenotype in the familial atypical multiple-mole melanoma-pancreatic
carcinoma syndrome. Cancer 2003; 98: 798–804
93 Vasen HF, Gruis NA, Frants RR et al. Risk of developing pancreatic cancer
in families with familial atypical multiple mole melanoma associated
with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer
2000; 87: 809–811
94 Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers
other than breast or ovarian. MedGenMed 2005; 7: 60
95 Asperen CJvan, Brohet RM, Meijers-Heijboer EJ et al. Cancer risks in
BRCA2 families: estimates for sites other than breast and ovary.
J Med Genet 2005; 42: 711–719
96 Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers.
J Natl Cancer Inst 2002; 94: 1358–1365
97 Lilley M, Gilchrist D. The hereditary spectrum of pancreatic cancer:
the Edmonton experience. Can J Gastroenterol 2004; 18: 17–21
98 Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers
of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214–218
99 Geoffroy-Perez B, Janin N, Ossian K et al. Cancer risk in heterozygotes
for ataxia-telangiectasia. Int J Cancer 2001; 93: 288–293
100 Giardiello FM, Offerhaus GJ, Lee DH et al. Increased risk of thyroid and
pancreatic carcinoma in familial adenomatous polyposis. Gut 1993;
34: 1394–1396
101 Couch FJ, Johnson MR, Rabe K et al. Germ line Fanconi anemia complementation
group C mutations and pancreatic cancer. Cancer Res
2005; 65: 383–386
102 Howes N, Lerch MM, Greenhalf W et al. Clinical and genetic characteristics
of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol
2004; 2: 252–261
103 Lowenfels AB, Maisonneuve P, DiMagno EP et al. Hereditary pancreatitis
and the risk of pancreatic cancer. International Hereditary Pancreatitis
Study Group. J Natl Cancer Inst 1997; 89: 442–446
104 Kimmey MB, Bronner MP, Byrd DR et al. Screening and surveillance
for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56:
S82–86
105 Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic
cancer. Gastroenterology 1995; 109: 247–251
106 Karlson BM, Ekbom A, Josefsson S et al. The risk of pancreatic cancer
following pancreatitis: an association due to confounding? Gastroenterology
1997; 113: 587–592
Adler G et al. S3-Guideline “Exocrine Pancreatic… Z Gastroenterol 2008; 46: 449–482
107 Lowenfels AB, Maisonneuve P, Cavallini G et al. Pancreatitis and the
risk of pancreatic cancer. International Pancreatitis Study Group. N
Engl J Med 1993; 328: 1433–1437
108 Malka D, Hammel P, Maire F et al. Risk of pancreatic adenocarcinoma
in chronic pancreatitis. Gut 2002; 51: 849–852
109 Talamini G, Falconi M, Bassi C et al. Incidence of cancer in the course
of chronic pancreatitis. Am J Gastroenterol 1999; 94: 1253–1260
110 Chari ST, Leibson CL, Rabe KG et al. Probability of pancreatic cancer
following diabetes: a population-based study. Gastroenterology
2005; 129: 504–511
111 Coughlin SS, Calle EE, Teras LR et al. Diabetes mellitus as a predictor of
cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;
159: 1160–1167
112 Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A et al. Type-
II diabetes and pancreatic cancer. A meta-analysis of 36 studies. Br J
Cancer 2005; 92: 2076–2083
113 Stolzenberg-Solomon RZ, Graubard BI, Chari S et al. Insulin, glucose,
insulin resistance, and pancreatic cancer in male smokers. Jama
2005; 294: 2872–2878
114 Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based
cohort of patients hospitalized with diabetes mellitus
in Denmark. J Natl Cancer Inst 1997; 89: 1360–1365
115 Calle EE, Murphy TK, Rodriguez C et al. Diabetes mellitus and pancreatic
cancer mortality in a prospective cohort of United States adults.
Cancer Causes Control 1998; 9: 403–410
116 Chow WH, Gridley G, Nyren O et al. Risk of pancreatic cancer following
diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer
Inst 1995; 87: 930–931
117 Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other
medical conditions and familial history of cancer as risk factors for
pancreatic cancer. Br J Cancer 1999; 80: 1830–1837
118 Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic
cancer. A meta-analysis. Jama 1995; 273: 1605–1609
119 Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic
cancer. Italian Pancreatic Cancer Study Group. N Engl J Med
1994; 331: 81–84
120 Rousseau MC, Parent ME, Pollak MN et al. Diabetes mellitus and cancer
risk in a population-based case-control study among men from
Montreal, Canada. Int J Cancer 2006; 118: 2105–2109
121 Bjornsson E, Ismael S, Nejdet S et al. Severe jaundice in Sweden in the
new millennium: causes, investigations, treatment and prognosis.
Scand J Gastroenterol 2003; 38: 86–94
122 Reisman Y, Gips CH, Lavelle SM et al. Clinical presentation of (subclinical)
jaundice – the Euricterus project in The Netherlands. United
Dutch Hospitals and Euricterus Project Management Group. Hepatogastroenterology
1996; 43: 1190–1195
123 Watanabe I, Sasaki S, Konishi M et al. Onset symptoms and tumor locations
as prognostic factors of pancreatic cancer. Pancreas 2004;
28: 160–165
124 Balthazar EJ. Pancreatitis associated with pancreatic carcinoma. Preoperative
diagnosis: role of CT imaging in detection and evaluation.
Pancreatology 2005; 5: 330–344
125 Mujica VR, Barkin JS, Go VL. Acute pancreatitis secondary to pancreatic
carcinoma. Study Group Participants. Pancreas 2000; 21: 329–
332
126 Adamek HE, Albert J, Breer H et al. Pancreatic cancer detection with
magnetic resonance cholangiopancreatography and endoscopic retrograde
cholangiopancreatography: a prospective controlled study.
Lancet 2000; 356: 190–193
127 Hanninen EL, Ricke J, Amthauer H et al. Magnetic resonance cholangiopancreatography:
image quality, ductal morphology, and value
of additional T2- and T 1-weighted sequences for the assessment of
suspected pancreatic cancer. Acta Radiol 2005; 46: 117–125
128 Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and
prediction of unresectability using the tumor-associated antigen
CA19–9. Pancreas 1994; 9: 731–734
129 Nazli O, Bozdag AD, Tansug T et al. The diagnostic importance of CEA
and CA19–9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology
2000; 47: 1750–1752
130 Ritts Jr RE, Nagorney DM, Jacobsen DJ et al. Comparison of preoperative
serum CA19–9 levels with results of diagnostic imaging modalities
in patients undergoing laparotomy for suspected pancreatic or
gallbladder disease. Pancreas 1994; 9: 707–716
Downloaded by: Thieme Verlagsgruppe. Copyrighted material.